BiotechTube
EnGenome

EnGenome

Pavia, Italy· Est.
engenome.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $6.5M

Overview

EnGenome is a private, revenue-generating diagnostics company founded in 2011 as a spin-off from the University of Pavia. It has developed the IVDR-certified eVai platform, an AI-powered software-as-a-service (SaaS) solution for the interpretation of genomic variants, primarily targeting the rare disease diagnostic market. The company combines a strong academic foundation with a commercial focus, achieving regulatory milestones and expanding its cloud-based services across Europe.

Rare Diseases

Technology Platform

eVai: AI-powered, guideline-based SaaS platform for monogenic and digenic variant interpretation and diagnosis of rare diseases. Integrates continuous learning and is IVDR-certified. Complementary VarChat tool uses Generative AI for literature summarization on variants.

Funding History

2
Total raised:$6.5M
Series A$5M
Seed$1.5M

Opportunities

The stringent EU IVDR regulation creates a high barrier to entry, favoring early-certified players like EnGenome.
The growing adoption of clinical genomics and the shift to cloud-based SaaS models in healthcare present significant expansion opportunities.
The high unmet need in rare disease diagnosis ensures strong market demand for tools that improve diagnostic yield and speed.

Risk Factors

The company faces intense competition from larger, well-funded players in the clinical genomics software market.
Maintaining technological edge and regulatory compliance (IVDR, potential FDA) requires continuous, costly R&D.
Commercial success depends on overcoming long sales cycles and convincing risk-averse clinical labs to adopt new software.

Competitive Landscape

EnGenome competes in the clinical variant interpretation market against established players like Sophia Genetics, Fabric Genomics, and Qiagen's Clinical Insight, as well as the bioinformatics suites of sequencing giants like Illumina. Its differentiation lies in its specific focus on digenic interpretation, IVDR certification, and its innovative VarChat AI literature tool.

More companies in Diagnostics & Precision Medicine →More companies in Italy →